Wiedmeier Julia E, Mountjoy Luke J, Buras Matthew R, Kosiorek Heidi E, Coppola Kyle E, Verona Patricia M, Cook Curtiss B, Karlin Nina J
Department of Internal Medicine, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA.
Division of Hematology & Medical Oncology, Mayo Clinic Hospital, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA.
Future Sci OA. 2020 Oct 26;7(1):FSO639. doi: 10.2144/fsoa-2020-0117.
We examined the association between diabetes and survival in patients with acute and chronic myeloid leukemia and the association of leukemia with glycemic control.
PATIENTS & METHODS: Patients with leukemia with and without diabetes (2007-2015) were retrospectively identified and matched 1:1 (n = 70 per group). Overall survival was estimated by the Kaplan-Meier method. Hemoglobin A and glucose levels the year after leukemia diagnosis were compared by mixed models.
Among 25 of 70 patients with diabetes, mean hemoglobin A during the year after leukemia diagnosis was 6.8%. Kaplan-Meier-estimated 3-year survival was 46% for diabetes patients versus 45% for controls (p = 0.79).
No associations were found between leukemia, diabetes, survival and glycemic control.
我们研究了糖尿病与急性和慢性髓系白血病患者生存率之间的关联，以及白血病与血糖控制之间的关联。
回顾性确定2007年至2015年患有和未患有糖尿病的白血病患者，并按1:1进行匹配（每组n = 70）。采用Kaplan-Meier法估计总生存率。通过混合模型比较白血病诊断后一年的糖化血红蛋白和血糖水平。
在70例糖尿病患者中的25例中，白血病诊断后一年的平均糖化血红蛋白为6.8%。Kaplan-Meier估计糖尿病患者的3年生存率为46%，而对照组为45%（p = 0.79）。
未发现白血病、糖尿病、生存率和血糖控制之间存在关联。
